Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
TA-02 is a derivative of the p38 MAPK inhibitor SB 203580 (Item Nos. 13067 | 13344) and an inducer of cardiomyocyte differentiation.1 It is cardiomyogenic, increasing expression of the cardiomyocyte marker NKX2-5 by greater than 2-fold and decreasing expression of mesoderm markers and the pre-cardiac marker Isl-1 in HES-3 NKX2-5eGFP/w cells when applied after embryoid body formation at a concentration of 5 μM. TA-02 inhibits casein kinase 1ε (CK1ε) and CK1D and reduces expression of Wnt/β-catenin signaling pathway members, activities that positively correlate with its cardiomyogenic activity.
WARNING This product is not for human or veterinary use.
1. Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. J. Mol. Cell. Cardiol. 80, 56-70 (2015).